UK’s NHS Cites Significant Savings From Generics And Biosimilars
A Third Of £1.2bn Total Over Three Years Came From Adalimumab, NHS Reveals
Savings made through the use of generics and biosimilars have been highlighted by the UK’s NHS, with the organization pointing to savings of £1.2bn over three years, a third of which came from Humira biosimilars alone.
